Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。
期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-026-01365-6
Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M